Gene Fusion Type Determination: Principles, Methods, and Clinical Applications

Gene fusion type determination is a molecular diagnostic process used to identify chromosomal rearrangements, fusion partners, and transcript variants that drive cancer progression and inform targeted therapy decisions. By employing validated methods such as FISH, RT-PCR, and next-generation sequencing (NGS), accredited third-party laboratories deliver accurate fusion profiling for oncology diagnosis, prognosis, and treatment selection. This article provides a comprehensive technical overview of gene fusion testing, including sample requirements, testing items, analytical methods, and clinical applications.

Technical Overview

Gene fusions arise from structural chromosomal rearrangements—including translocations, inversions, interstitial deletions, and complex rearrangements—that juxtapose coding sequences from two distinct genes into a single hybrid transcript. The resulting chimeric proteins frequently function as oncogenic drivers by constitutively activating kinase signaling, altering transcriptional regulation, or disrupting normal cellular homeostasis. Classic examples include BCR::ABL1 in chronic myeloid leukemia, PML::RARA in acute promyelocytic leukemia, and EML4::ALK in non-small cell lung cancer.

Gene fusion type determination goes beyond simple positive/negative detection. It involves the precise characterization of the 5' fusion partner, the 3' fusion partner, the genomic or transcriptomic breakpoint location, and the specific transcript variant expressed. This level of resolution matters clinically: different BCR::ABL1 isoforms (p190, p210, p230) define distinct disease entities, and specific EML4::ALK variants (v1, v3a/b, v2, v5) may influence response to ALK inhibitors and disease aggressiveness.

Reliable fusion typing requires rigorous laboratory infrastructure, validated analytical workflows, and robust quality management systems. Testing should be performed in facilities operating in accordance with ISO 15189 (medical laboratories) or ISO/IEC 17025 (testing and calibration laboratories) requirements, with appropriate pre-analytical controls, assay validation, and post-analytical reporting standards.

Testing Samples

Formalin-Fixed Paraffin-Embedded (FFPE) Tissue

FFPE tissue is the most commonly submitted specimen for solid tumor fusion testing. Sections should contain adequate tumor cellularity (typically ≥20%), and pathologist review with tumor enrichment (macrodissection) is recommended to maximize assay sensitivity. RNA extracted from FFPE is often fragmented; therefore, assays designed for short amplicons or anchored capture chemistries are preferred for degraded input material.

Fresh or Frozen Tissue

Fresh or flash-frozen tissue provides the highest quality nucleic acids and is ideal for comprehensive RNA-based methods such as whole-transcriptome sequencing. Samples should be collected under sterile conditions, transported on dry ice or in RNA stabilization reagent, and processed promptly to minimize RNA degradation by endogenous ribonucleases.

Whole Blood and Bone Marrow Aspirate

For hematologic malignancies, peripheral blood or bone marrow aspirates collected in EDTA anticoagulant tubes are standard specimens. Bone marrow is generally preferred when the marrow is involved, as it yields higher leukemic burden. For BCR::ABL1 quantification, baseline samples must be collected prior to therapy initiation to establish the reference transcript level.

Plasma and Circulating Nucleic Acids

Cell-free RNA (cfRNA) and circulating tumor DNA (ctDNA) from plasma enable minimally invasive "liquid biopsy" fusion detection, particularly useful when tissue is unavailable or when serial monitoring is required. Two 10 mL Streck-type or EDTA tubes processed within the recommended stability window are typically required.

Cytology Specimens

Cell blocks, ThinPrep suspensions, and fine-needle aspiration materials are acceptable when cellularity is sufficient. These specimens are especially relevant for lung cancer diagnostics where biopsy tissue is limited and must be prioritized across multiple biomarker tests.

Testing Items

Gene fusion type determination encompasses several distinct analytical outputs, which may be ordered individually or as an integrated panel:

• Fusion partner identification: Determination of both the 5' and 3' gene partners involved in the rearrangement, such as EML4::ALK, CD74::ROS1, KIF5B::RET, or ETV6::NTRK3.
• Breakpoint localization: Mapping of the intronic or exonic breakpoint at the genomic or RNA level, which informs transcript architecture and may affect therapeutic options.
• Transcript variant typing: Discrimination of expressed isoforms, including BCR::ABL1 e13a2/e14a2 (p210), e1a2 (p190), e19a2 (p230), and EML4::ALK variants v1 through v5.
• Fusion panel screening: Multiplexed detection of clinically actionable fusions across ALK, ROS1, RET, NTRK1/2/3, MET exon 14 skipping, FGFR1/2/3, ERG, EWSR1, and related targets.
• Quantitative transcript monitoring: Measurement of fusion transcript levels normalized to reference genes, reported on the International Scale (IS) for BCR::ABL1, used for response assessment and minimal residual disease (MRD) tracking.
• Novel fusion discovery: Unbiased detection of previously uncharacterized fusions through capture-based or whole-transcriptome RNA sequencing.

Testing Methods

Fluorescence In Situ Hybridization (FISH)

FISH uses labeled DNA probes hybridizing to target loci on metaphase or interphase chromosomes. Break-apart probe strategies (commonly applied to ALK, ROS1, RET, NTRK, and EWSR1) detect rearrangement of a single locus without requiring knowledge of the partner, while dual-fusion probes confirm specific two-gene events such as BCR::ABL1. FISH works well on FFPE and is highly sensitive, but it does not identify the fusion partner or transcript variant, and interpretation requires experienced analysts.

Reverse Transcription PCR (RT-PCR) and Quantitative RT-PCR

RT-PCR amplifies fusion-specific transcripts using primers flanking known breakpoints. It offers high analytical sensitivity (down to 10⁻⁴ to 10⁻⁶ for quantitative assays), rapid turnaround, and precise isoform discrimination. Real-time quantitative RT-PCR (qRT-PCR) with standardized reference materials enables international-standard reporting essential for tyrosine kinase inhibitor therapy monitoring. Its principal limitation is the inability to detect fusions with unknown partners or novel breakpoints.

Next-Generation Sequencing (NGS)

NGS-based approaches include targeted anchored multiplex RNA panels, hybrid-capture DNA/RNA panels, and whole-transcriptome sequencing (RNA-seq). Anchored PCR and capture-based chemistries permit partner-agnostic fusion detection, including novel rearrangements and rare variants. RNA sequencing additionally confirms transcript expression, which strengthens clinical interpretation. NGS requires robust bioinformatics pipelines with validated fusion-calling algorithms, orthogonal confirmation of novel events, and appropriate contamination controls.

Immunohistochemistry (IHC)

IHC provides a rapid, cost-effective screening surrogate for fusions that drive overexpression of the 3' partner protein, such as ALK, ROS1, and pan-Trk (NTRK). Positive IHC results generally warrant confirmatory molecular testing when the fusion partner or variant must be established for therapeutic planning.

Conventional Karyotyping and Metaphase Analysis

G-banded karyotyping visualizes balanced and unbalanced chromosomal alterations genome-wide and remains valuable for initial characterization of hematologic malignancies, though its resolution (typically 5–10 Mb) is insufficient for precise breakpoint mapping. Spectral karyotyping (SKY) and multiplex FISH (M-FISH) supplement conventional analysis for complex rearrangements.

Method selection depends on sample type, nucleic acid quality, required sensitivity, and clinical context. Laboratories should follow recognized quality frameworks, such as ISO 15189 and ISO/IEC 17025, and participate in external quality assessment programs to ensure analytical validity and result comparability.

Applications

Gene fusion type determination supports critical decision points across oncology and molecular medicine:

• Targeted therapy selection: Identification of ALK, ROS1, RET, and NTRK fusions qualifies patients for corresponding tyrosine kinase inhibitors or TRK inhibitors, while FGFR fusions guide FGFR-targeted treatment in cholangiocarcinoma, urothelial carcinoma, and other malignancies.
• Hematologic diagnosis and classification: BCR::ABL1 confirms chronic myeloid leukemia, PML::RARA confirms acute promyelocytic leukemia, and rearrangements such as RUNX1::RUNX1T1 and CBFB::MYH11 refine acute myeloid leukemia classification under current WHO and ELN frameworks.
• Sarcoma subtyping: EWSR1, SS18, FOXO1, and FUS rearrangements are defining features of Ewing sarcoma, synovial sarcoma, alveolar rhabdomyosarcoma, and myxoid liposarcoma, respectively.
• Therapy response monitoring and MRD: Serial quantitative measurement of BCR::ABL1 transcripts on the International Scale guides treatment escalation, de-escalation, and discontinuation decisions.
• Prognostic stratification: Specific fusion variants carry distinct prognostic implications, informing risk-adapted treatment intensity in both solid and hematologic cancers.
• Resistance mechanism analysis: Detection of secondary rearrangements or fusion-dependent resistance mutations guides subsequent-line therapy selection.
• Clinical research and biomarker discovery: Unbiased RNA sequencing in research settings continues to reveal novel fusion events and expand the roster of actionable targets.

FAQ

What is the difference between fusion detection and fusion type determination?

Fusion detection answers whether a rearrangement is present, typically via FISH or IHC. Fusion type determination goes further by specifying the fusion partners, breakpoint positions, and expressed transcript variant, which is often necessary for therapy selection, prognostic assessment, and standardized monitoring.

Which method is most appropriate for FFPE samples with limited tissue?

For limited FFPE tissue, a multiplexed NGS RNA panel using short amplicons or anchored capture chemistry is generally preferred because it interrogates many targets simultaneously from degraded RNA. FISH performed on serial sections is an acceptable alternative when only a single gene locus is clinically relevant.

Can FISH and RT-PCR results ever disagree?

Yes. Discrepancies occur when a rearrangement is detected by FISH but does not produce an expressed fusion transcript detectable by RT-PCR, or when the breakpoint falls outside PCR primer coverage. In such cases, RNA-based NGS is recommended as a confirmatory and partner-agnostic method.

What sample quality metrics are required for RNA-based fusion testing?

Laboratories typically require a minimum RNA input (often 10–100 ng depending on the assay) with acceptable purity ratios and evidence of amplifiable short fragments. DV200 (percentage of RNA fragments >200 nucleotides) is more informative than RIN for FFPE-derived RNA, with DV200 ≥30% commonly accepted for anchored NGS assays.

How are novel fusions validated before clinical reporting?

Novel fusion calls discovered by NGS should be confirmed using orthogonal methods such as RT-PCR with Sanger sequencing, FISH with breakpoint-spanning probes, or independent library preparation. Reports should clearly distinguish confirmed events from candidate findings and include relevant interpretive commentary.

What turnaround time should be expected?

Typical turnaround times range from 1–3 working days for single-target FISH or RT-PCR assays to 7–14 calendar days for comprehensive NGS panels, depending on specimen type, test complexity, and confirmatory testing requirements. Urgent diagnostics, such as PML::RARA confirmation, should be prioritized with expedited workflows.

Is fusion testing covered by quality standards?

Yes. Reputable testing is performed under quality management systems conforming to ISO 15189 or ISO/IEC 17025, with documented assay validation covering accuracy, precision, limit of detection, and reportable range, complemented by regular participation in external quality assessment schemes.